Should I buy or sell VolitionRx stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VNRX shares. View VNRX analyst ratings or view top-rated stocks .

What is VolitionRx's stock price target for 2024?

1 Wall Street research analysts have issued twelve-month price targets for VolitionRx's stock. Their VNRX share price targets range from $2.50 to $2.50. On average, they expect the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 292.6% from the stock's current price. View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts .

How have VNRX shares performed in 2023?

VolitionRx's stock was trading at $1.34 at the beginning of 2023. Since then, VNRX stock has decreased by 52.5% and is now trading at $0.6367. View the best growth stocks for 2023 here .

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSE:VNRX) posted its earnings results on Tuesday, November, 14th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. The firm earned $0.17 million during the quarter, compared to the consensus estimate of $0.26 million. VolitionRx had a negative net margin of 5,201.69% and a negative trailing twelve-month return on equity of 7,185.73%.

Who are VolitionRx's major shareholders?

VolitionRx's stock is owned by a number of retail and institutional investors. Top institutional investors include Lagoda Investment Management L.P. (4.97%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gaetan Michel, Guy Archibald Innes, Jacob Vincent Micallef, Martin Charles Faulkes, Phillip Barnes and Salvatore Thomas Butera. View institutional ownership trends .

How do I buy shares of VolitionRx?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

VolitionRx Stock Price, News & Analysis (NYSE:VNRX)

$0.64

-0.02 (-3.09%)

(As of 04:38 PM ET)

Compare

Today's Range: $0.63
▼
$0.70
50-Day Range: $0.62
▼
$0.88
52-Week Range: $0.58
▼
$2.74

Volume: 137,039 shs
Average Volume: 150,152 shs
Market Capitalization: $50.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

About VolitionRx Stock (NYSE:VNRX)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company is based in Henderson, Nevada.

VNRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VNRX Stock News Headlines

November 17, 2023 | finance.yahoo.com

Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society

November 8, 2023 | proactiveinvestors.com

VolitionRx to host Q3 earnings call on November 15

December 8, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

October 28, 2023 | markets.businessinsider.com

VolitionRX’s Innovative Cancer Detection Platform: A Promising Investment – An Analyst’s Perspective

See More Headlines

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:VNRX
CUSIP: N/A
CIK: 93314
Web: N/A
Phone: 646-650-1351
Fax: 65 32 8172 5651
Employees: 114
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.50
High Stock Price Target: $2.50
Low Stock Price Target: $2.50
Potential Upside/Downside: +280.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,270,000.00
Net Margins: -5,201.69%
Pretax Margin: -5,255.45%
Return on Equity: -7,185.73%
Return on Assets: -165.30%

Debt

Debt-to-Equity Ratio: 0.56
Current Ratio: 0.69
Quick Ratio: 0.69

Sales & Book Value

Annual Sales: $651,044.00
Price / Sales: 79.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.05) per share
Price / Book: -13.14

Miscellaneous

Outstanding Shares: 78,686,000
Free Float: 66,568,000
Market Cap: $51.70 million
Optionable: Optionable
Beta: 1.61

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Martin Charles Faulkes Ph.D. (Age 79)
Executive Chairman
Comp: $227.63k
Mr. Cameron Reynolds MBA (Age 52)
Founder, CEO, President & Director
Comp: $538.66k
Mr. Terig Hughes (Age 53)
CFO & Treasurer
Comp: $338.74k
Dr. Gaetan Michel Ph.D. (Age 50)
Chief Operating Officer
Comp: $445.06k
Dr. Jacob Vincent Micallef MBA (Age 67)
Ph.D., Chief Scientific Officer
Comp: $571.55k
Mr. Scott Powell Ph.D. (Age 49)
Executive Vice President of Investor Relations
Mr. Nicholas Plummer (Age 52)
Group General Counsel
Ms. Louise Batchelor Day (Age 52)
Group Chief Marketing & Communications Officer
Mr. Thomas Bygott
Sales & Marketing Director
Mr. Gael Forterre M.B.A. (Age 42)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VNRX Stock Analysis - Frequently Asked Questions

Should I buy or sell VolitionRx stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VNRX shares.
View VNRX analyst ratings or view top-rated stocks.
What is VolitionRx's stock price target for 2024?: 1 Wall Street research analysts have issued twelve-month price targets for VolitionRx's stock. Their VNRX share price targets range from $2.50 to $2.50. On average, they expect the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 292.6% from the stock's current price.
View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts.
How have VNRX shares performed in 2023?: VolitionRx's stock was trading at $1.34 at the beginning of 2023. Since then, VNRX stock has decreased by 52.5% and is now trading at $0.6367.
View the best growth stocks for 2023 here.
How were VolitionRx's earnings last quarter?: VolitionRx Limited (NYSE:VNRX) posted its earnings results on Tuesday, November, 14th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.01. The firm earned $0.17 million during the quarter, compared to the consensus estimate of $0.26 million. VolitionRx had a negative net margin of 5,201.69% and a negative trailing twelve-month return on equity of 7,185.73%.

Who are VolitionRx's major shareholders?: VolitionRx's stock is owned by a number of retail and institutional investors. Top institutional investors include Lagoda Investment Management L.P. (4.97%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gaetan Michel, Guy Archibald Innes, Jacob Vincent Micallef, Martin Charles Faulkes, Phillip Barnes and Salvatore Thomas Butera.
View institutional ownership trends.
How do I buy shares of VolitionRx?: Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:VNRX) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial